Pacific Biosciences of California, Inc. has entered into an agreement to exchange $459 million of its 2028 Convertible Senior Notes for $200 million of new 2029 Convertible Senior Notes, 20.45 million shares of common stock, and a $50 million cash payment to SB Northstar LP, with the transaction expected to close around November 21, 2024.